Comparison
While PT-141 is FDA-approved for treatment of hypoactive sexual desire disorder in premenopausal women and is studied for sexual dysfunction in other populations, increasing sexual desire via CNS melanocortin pathways42101, Tesamorelin is FDA-approved to reduce excess visceral adipose tissue in HIV-associated lipodystrophy and is studied for broader body-composition, NAFLD, and cognitive effects via GH/IGF-1 axis modulation1893.
While PT-141 works as the synthetic melanocortin receptor agonist bremelanotide, an analog of α-MSH that activates central MC3R and MC4R to modulate neuronal circuits governing sexual desire and arousal3242101, Tesamorelin is a full-length 44-amino-acid GHRH analog with an N-terminal trans-3-hexenoic acid modification that binds GHRHR, activating cAMP/PKA signaling to increase endogenous GH and IGF-1, with improved stability versus native GHRH182893102.
PT-141 is 7 amino acids long, whereas Tesamorelin is longer as it has a length of 44 amino acids. PT-141 is made up of a sequence of sequence data not available in the current dataset. Tesamorelin is made up of a sequence of Tyrosine, Alanine, Aspartic acid, Alanine, Isoleucine, Phenylalanine, Threonine, Asparagine, Serine, Tyrosine, Arginine, Lysine, Valine, Leucine, Glycine, Glutamine, Leucine, Serine, Alanine, Arginine, Lysine, Leucine, Leucine, Glutamine, Aspartic acid, Isoleucine, Methionine, Serine, Arginine, Glutamine, Glutamine, Glycine, Glutamic acid, Serine, Asparagine, Glutamine, Glutamic acid, Arginine, Glycine, Alanine, Arginine, Alanine, Arginine, Leucine.
PT-141
POMC
Tesamorelin
GHRH
No related articles are linked to these peptides yet.